Journal article
Resolvin D2 supports MCF-7 cell proliferation via activation of estrogen receptor
N Al-Zaubai, CN Johnstone, MM Leong, J Li, M Rizzacasa, AG Stewart
Journal of Pharmacology and Experimental Therapeutics | AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS | Published : 2014
Abstract
Inflammation has been implicated in tumor initiation, angiogenesis, and metastasis, and linked to the development of more aggressive, therapy-resistant estrogen receptor (ER)-positive breast cancer. Resolvin D2 (RvD2) is a potent anti-inflammatory lipid mediator. As RvD2 may be synthesized within breast tumors by both tumor cells and the surrounding stroma cells and is present in plasma at bioactive concentrations, we sought to characterize the impact of RvD2 on cell processes underlying breast tumor growth and spread. Trypan-blue exclusion, transfection with estrogen response element (ERE) reporter, real-time quantitative polymerase chain reaction, competitive radioligand binding assays, We..
View full abstractGrants
Funding Acknowledgements
This work was supported by the National Health and Medical Research Council of Australia [Grant 1023185].